24/7 Market News Snapshot 24 September, 2024 – Lipella Pharmaceuticals Inc. Common Stock (NASDAQ:LIPO)

September 24, 2024

DENVER, Colo., 24 September, 2024 (247marketnews.com) – (NASDAQ:LIPO) are discussed in this article.
Lipella Pharmaceuticals Inc. has recently captured significant attention in the investment community with a remarkable surge in its stock price, now trading at $0.529 after an impressive increase of 28.80% from its opening price of $0.439. This surge, marked by a trading volume of over 5.13 million shares, indicates heightened investor interest and confidence in the company’s innovative therapies and promising future.

On the clinical front, Lipella is gaining recognition for its pioneering work in developing LP-310, an oral rinse currently undergoing a Phase 2a clinical trial aimed at treating Oral Lichen Planus (OLP), a debilitating condition with no FDA-approved treatments available. Preliminary results from the trial have been encouraging, with three participants successfully completing a four-week regimen of LP-310. The trial is focused on assessing the safety, tolerability, and efficacy of the formulation, with initial findings indicating that LP-310 is well tolerated, a vital factor for patient compliance.

Dr. Michael Chancellor, the Chief Medical Officer, emphasized the importance of these results, stating that the tolerability of LP-310 is particularly promising for patients experiencing the severe symptoms associated with OLP. The formulation is derived from Lipella’s lead candidate, LP-10, and aims to offer a more effective treatment option that addresses the underlying causes of OLP while minimizing systemic toxicity.

The multi-center trial is ongoing, actively recruiting participants aged 18 and older, with expectations for completion by mid-2025 and top-line data anticipated by the end of 2024. As Lipella Pharmaceuticals steadily advances its mission to expand treatment options for OLP, the biotech firm positions itself as a key player in the industry, attracting attention from both investors and medical professionals alike.

Related news for (LIPO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.